HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Shijiazhuang Biopharmaceuticals

Shijiazhuang has parallel capabilities in chemical drugs, biologics, modern traditional medicine, medical devices, and health products, supported by large manufacturers and specialist development platforms.

Formation and regional foundations

The industry expanded from antibiotics and active ingredients into formulations, biologics, and modern traditional medicine. The high-tech and economic development zones host production, while the international biomedicine park supports development, pilot work, and project entry.

Shijiazhuang biopharma concentrates research, active ingredients, dosage forms, packaging equipment and specialist services. Moving a medicine from laboratory process to scale requires operation within approved formulation, site and quality systems. Industry scale provides context; approvals, manufacturing records and release responsibility determine the actual product.

Core geography: Shijiazhuang High-tech Zone–Economic Development Zone biopharma corridor

Shijiazhuang Biopharma Value Chain

From Candidate to Hospital and Retail Endpoint

Nodes show common roles and do not imply shared approvals or lines among the three companies.

  • Research, analytics and clinical interface — Retains links among candidate, method, sample, protocol and version.
  • Scale manufacturing and dosage forms — Controls materials, parameters, yield and environment under the approved process.
  • Excipients, packaging and equipment — Checks compatibility, supplier changes, cleaning and calibration.
  • Hospitals, retail and logistics — Matches storage, lot, expiry, returns and recall.
  • Registration, compliance and quality systems — Manages change, deviation, stability, release and safety-reporting duties.
  • Research and manufacturing services — Defines samples, methods, transfer, data ownership and subcontracting.

01 · Output, Growth, Rankings and Park Entities Span Two Levels

A city industry table does not directly match a park register.

A Hebei industry authority reports Shijiazhuang biopharma output of RMB 125.72 billion in 2024, growth of 10.7 percent and five local firms in a pharmaceutical top 100. A municipal account separately records more than 300 enterprises in the international biopharma park. The first three describe a city industry, whereas the last counts park entities.

Park entities may include research, testing, devices, logistics and newly registered firms with no production. Output aggregates economic activity under a defined classification. Dividing city output by the park count would average unlike entity types and geographic scopes.

An update pairs output and growth from one statistical year, retains the ranking edition for top-100 firms, and gives the park count its tenant definition and as-of date. Drug approvals, manufacturing licences and active status use separate fields. Park totals do not fill missing company disclosures.

  • Retain year, statistical boundary and entity definition first.

02 · More Than 300 Park Entities Need Business Classification

The two-main, three-support structure is spatial, not a product route.

Municipal information records more than 300 enterprises in the international biopharma park, while another city account describes a two-main, three-support spatial pattern. One indicates park concentration; the other summarises city geography. Neither means every entity holds a medicine manufacturing qualification.

A research company may have only laboratories, a contract lab uses analytical instruments, a packaging firm manages materials and clean production, and a medicine plant performs the relevant manufacturing. Registered, research and manufacturing addresses can differ. Treating a park address as a plant address misaligns licence checks.

The park register adds business type, actual site, licence scope, major equipment and current state. Proposed, commissioning, suspended and service-only entities are marked explicitly. Geography can plan visits, but product supply links still require contracts or disclosure from both parties.

  • Separate research, manufacturing, service and pre-operational entities.

03 · Licensing Stands between Industry Layout and a Medicine Line

Planning support does not change an approved formula, site or process.

The two-main, three-support pattern organises Shijiazhuang biopharma geography, while the Hebei pharmaceutical plan provides a broader industry direction. Both can support research, manufacturing and services. Neither automatically expands the product, site or strength on a medicine approval.

Scale-up changes mixing, heat transfer, oxygen transfer, filtration and drying. The same formula on new equipment can create different impurity or dissolution behaviour. Matching ingredient proportions alone does not prove equivalence to the original process.

Technology transfer first lists approved elements, controlled parameters, critical material attributes and analytical methods, then assesses differences in the receiving facility and equipment. Trial lots retain deviations, yield, in-process and stability results. Commercial planning changes only after the regulatory category and approval or filing status are clear.

  • Technology transfer and retrofit start with regulatory impact.

04 · CSPC Identity Does Not Replace a Product Approval

Provincial direction and a company profile have distinct scopes.

The Hebei pharmaceutical plan describes provincial direction, while the CSPC homepage identifies a specific pharmaceutical operator. The two levels explain environment and company entry point. They neither grant CSPC every technology in the plan nor replace approval information for a medicine.

One group may cover active ingredients, several dosage forms and research projects, with different holders, manufacturers and approved sites. A group brand on the pack does not identify the manufacturing legal person. Supplier control at group-name level can miss reassessment when a site changes.

A CSPC product engagement uses the approval number as its key and matches name, form, strength, holder, manufacturer and pack. The sample lot links its analytical report and stability conditions. Contractual quality responsibility rests on a confirmed legal entity rather than a broad group label.

  • Match name, dosage form, strength, holder and site item by item.

05 · CSPC and North China Pharmaceutical Do Not Share Production by Proximity

Approvals, equipment, data and customers remain separate by company.

Official company pages separately identify CSPC and North China Pharmaceutical as pharmaceutical operators. Their presence in the same Shijiazhuang industry shows multiple large entities in one city. The profiles do not jointly disclose contract manufacture, shared equipment or mutual material supply.

Fermentation, synthesis, purification, sterile work and solid dosage production require different facilities and cleaning controls. Possession of equipment does not allow one company to make any product owned by another. Contract manufacture also has to match approvals, a quality agreement and registration requirements.

Each company file separately records approval holder, site, commissioning party, contractor, product scope and validity. If a bilateral project exists, product, site and duties match across contract and quality agreement. A unilateral marketing statement does not become a confirmed supply relationship.

  • A shared city and business category do not prove contract manufacture.

06 · North China Pharmaceutical and Yiling Need Distinct Product Paths

Company profiles establish business entry points, not efficacy or interchangeability.

Company pages for North China Pharmaceutical and Yiling provide separate business entry points. A shared city does not imply common materials, dosage forms, research paths or healthcare customers. Corporate descriptions cannot compare clinical outcomes of particular medicines.

Chemical actives, fermentation products, multi-ingredient traditional medicines and finished dosage forms differ fundamentally in supply chain, critical attributes and stability. Similar-looking tablets may be non-interchangeable because active ingredients, release specifications and packaging differ. An industry map cannot guide a clinical choice for an individual patient.

For a product enquiry, obtain current approved instructions, approval information and manufacturer details before checking form, strength, storage and expiry. Qualified professionals and statutory channels handle medical use and adverse-reaction questions. A commercial buyer does not broaden indications.

  • Use approved information for indication, dosage form, use and risk.

07 · One Yiling Product Does Not Carry City Output

Company identity, industry scale and medicine evidence remain three levels.

Yiling company information identifies a Shijiazhuang pharmaceutical operator, while RMB 125.72 billion and 10.7 percent growth describe the city biopharma industry in 2024. The two sources connect only through geography. Industry figures are neither Yiling revenue nor sales for a medicine.

Post-market manufacturing changes, stability, complaints, returns and safety reports all return to a named approval and lot. A risk signal for one product is not reduced by city industry growth. Nor does industry growth prove inventory, hospital coverage or repeat purchase.

A Yiling product file uses approval number, trade name, form, strength, site and instruction version as one identity. Procurement records supply lot, expiry, transport temperature and returns, and routes quality events through the holder contact. Any product comparison uses evidence reviewed by the relevant regulator.

  • Industry growth supports no product efficacy, sales or share claim.

08 · Close the Loop from Technology Transfer to Dispatch Lot

One record chain links change, manufacture, release and recall.

Shijiazhuang 2024 figures show local biopharma scale and growth, while more than 300 entities in the international park indicate a dense field of possible contacts. These levels help screen geography and partners. Delivery of one medicine project requires approvals, equipment, people and lot records together.

Project start freezes product, regulatory state, deliverables, analytical methods and quality responsibility. After transfer samples pass, engineering and validation lots continue to check parameters, yield, impurities, uniformity and stability. Every deviation has investigation, affected scope and disposition.

Commercial release checks material genealogy, manufacturing records, facility and equipment status, test results, deviations and packaging. After dispatch, storage, returns, complaints and safety information remain linked to lots so affected stock can be located. Supply expansion pauses if a recall drill cannot trace within the time limit.

  • Sample, commercial lot and dispatch pack use one product identity.

Sources and reading notes

The 2024 output and growth measures, the count of local firms in a pharmaceutical top 100, and entities in the international biopharma park use city-industry and park scopes. They are not figures for CSPC, North China Pharmaceutical or Yiling and support no conclusion about therapeutic effect.

  • 2024 industry output: RMB 125.72bn
  • 2024 year-on-year growth: 10.7%
  • Local companies in the national pharmaceutical top 100: 5

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

  • CSPC — Hebei Department of Industry and Information Technology documents the local base of Shijiazhuang Biopharmaceuticals. The company’s official site describes related products or services and an operating presence in Shijiazhuang.
  • NCPC — Hebei Department of Industry and Information Technology documents the local base of Shijiazhuang Biopharmaceuticals. The company’s official site describes related products or services and an operating presence in Shijiazhuang.
  • Yiling Pharmaceutical — Hebei Department of Industry and Information Technology documents the local base of Shijiazhuang Biopharmaceuticals. The company’s official site describes related products or services and an operating presence in Shijiazhuang.
  • Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.